Atraverse Medical, a medical device company specializing in transseptal access technology, announced the close of a $29.4 million follow-on financing to accelerate growth. The raise builds upon $12.5 million in prior seed investment that was used to obtain FDA 510(k) clearance and begin early commercialization of HOTWIRE, the company's novel radiofrequency (RF) guidewire for left-heart access. The company has now raised more than $40 million of investment capital.
Designed to simplify left-heart access through universal sheath compatibility and a zero-exchange workflow, and engineered for enhanced echogenicity and increased rail stiffness, HOTWIRE is the focus of the company's current U.S. commercialization strategy.
Cleared by the FDA in May 2024, HOTWIRE is approaching its first 1,000 successful procedures across 10 different introducer sheaths as part of a limited market release. The device enables zero-exchange left-heart access and serves as a rail for catheter-based therapies. With universal sheath compatibility, HOTWIRE is designed to advance transseptal access technology, optimize procedural workflows, and support improved patient outcomes with a best-in-class platform for left-heart access.
